India, June 4 -- SciSparc Ltd. (SPRC), a clinical-stage biopharmaceutical company focused on central nervous system disorders, announced that its subsidiary NeuroThera Labs Inc. (NTLX) has completed the acquisition of a majority stake in CliniQuantum Ltd.
Under the purchase agreement, NeuroThera acquired approximately 54% of CliniQuantum's issued and outstanding shares in exchange for common shares valued at about CAD$9.46 million. In addition, CliniQuantum's selling shareholders may be eligible for earn-out payments of up to $2.5 million, contingent on milestones such as patent filings and fundraising achievements.
CliniQuantum is a private Israeli technology company developing a platform that applies quantum simulation and Monte Carlo m...